(-0.34%) 5 018.39 points
(0.23%) 37 903 points
(-0.33%) 15 605 points
(0.10%) $79.08
(0.00%) $1.932
(0.90%) $2 331.90
(0.79%) $26.96
(1.02%) $964.60
(-0.45%) $0.933
(-0.59%) $11.03
(-0.32%) $0.798
(0.06%) $93.51
Live Chart Being Loaded With Signals
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide...
Stats | |
---|---|
今日成交量 | 5.63M |
平均成交量 | 686 607 |
市值 | 1.49B |
EPS | $0 ( 2023-05-04 ) |
Last Dividend | $0.125 ( 2019-02-01 ) |
Next Dividend | $0 ( N/A ) |
P/E | 21.09 |
ATR14 | $0.299 (0.88%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-01-31 | Williams Felicia | Sell | 10 274 | Common Stock |
2023-01-31 | Williams Felicia | Sell | 12 000 | Stock Option (Right to Buy) |
2023-01-31 | Williams Felicia | Sell | 8 740 | Stock Option (Right to Buy) |
2023-01-31 | Williams Felicia | Sell | 17 205 | Stock Option (Right to Buy) |
2023-01-31 | Williams Felicia | Sell | 5 796 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-88.83 |
Last 100 transactions |
Buy: 118 571 | Sell: 1 534 678 |
音量 相关性
Meridian Bioscience Inc 相关性 - 货币/商品
Meridian Bioscience Inc 财务报表
Annual | 2022 |
营收: | $333.02M |
毛利润: | $188.36M (56.56 %) |
EPS: | $0.960 |
FY | 2022 |
营收: | $333.02M |
毛利润: | $188.36M (56.56 %) |
EPS: | $0.960 |
FY | 2021 |
营收: | $317.90M |
毛利润: | $201.15M (63.27 %) |
EPS: | $1.650 |
FY | 2020 |
营收: | $253.67M |
毛利润: | $156.25M (61.60 %) |
EPS: | $1.080 |
Financial Reports:
No articles found.
Meridian Bioscience Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.00678 | 1990-11-29 |
Last Dividend | $0.125 | 2019-02-01 |
Next Dividend | $0 | N/A |
Payout Date | 2019-02-14 | |
Next Payout Date | N/A | |
# dividends | 114 | -- |
Total Paid Out | $9.88 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.53 | -- |
Div. Sustainability Score | 0.950 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0.115 | -- |
Year | Amount | Yield |
---|---|---|
1990 | $0 | 0.00% |
1991 | $0 | 0.00% |
1992 | $0 | 0.00% |
1993 | $0 | 0.00% |
1994 | $0 | 0.00% |
1995 | $0 | 0.00% |
1996 | $0 | 0.00% |
1997 | $0 | 0.00% |
1998 | $0 | 0.00% |
1999 | $0 | 0.00% |
2000 | $0 | 0.00% |
2001 | $0 | 0.00% |
2002 | $0 | 0.00% |
2003 | $0.160 | 3.50% |
2004 | $0.178 | 3.83% |
2005 | $0.213 | 2.70% |
2006 | $0.307 | 2.09% |
2007 | $0.434 | 2.63% |
2008 | $0.560 | 1.88% |
2009 | $0.680 | 2.60% |
2010 | $0.760 | 3.51% |
2011 | $0.760 | 3.21% |
2012 | $0.950 | 4.98% |
2013 | $0.570 | 2.75% |
2014 | $0.800 | 3.06% |
2015 | $0.800 | 4.88% |
2016 | $0.800 | 4.10% |
2017 | $0.500 | 2.80% |
2018 | $0.500 | 3.47% |
2019 | $0.125 | 0.74% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.197 | 1.500 | -3.93 | -5.90 | [0 - 0.5] |
returnOnAssetsTTM | -0.0528 | 1.200 | -1.760 | -2.11 | [0 - 0.3] |
returnOnEquityTTM | -0.0681 | 1.500 | -1.867 | -2.80 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.56 | 0.800 | 2.18 | 1.741 | [1 - 3] |
quickRatioTTM | 1.472 | 0.800 | 6.05 | 4.84 | [0.8 - 2.5] |
cashRatioTTM | 0.943 | 1.500 | 5.87 | 8.81 | [0.2 - 2] |
debtRatioTTM | 0.0682 | -1.500 | 8.86 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -65.48 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.00825 | 2.00 | -0.00275 | -0.00550 | [0 - 30] |
freeCashFlowPerShareTTM | -0.148 | 2.00 | -0.0740 | -0.148 | [0 - 20] |
debtEquityRatioTTM | 0.0914 | -1.500 | 9.63 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.534 | 1.000 | 4.43 | 4.43 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.197 | 1.000 | -5.93 | -5.93 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.0116 | 1.000 | -1.176 | -1.176 | [0.2 - 2] |
assetTurnoverTTM | 0.268 | 0.800 | -1.544 | -1.235 | [0.5 - 2] |
Total Score | 0.950 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -61.83 | 1.000 | -6.35 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0681 | 2.50 | -1.200 | -2.80 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.148 | 2.00 | -0.0493 | -0.148 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.00825 | 2.00 | -0.00275 | -0.00550 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 1.518 | 1.500 | 3.22 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.00295 | 1.000 | -2.57 | 0 | [0.1 - 0.5] |
Total Score | -0.720 |
Meridian Bioscience Inc
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。